FREMONT, CA ,
“Dr. Irwin is trustworthy, sincere, devoted to the work, and takes things that concern his patients seriously. We are grateful for him joining our study as the principal investigator,” said
Follow the link to hear the full interview with
ABVC BioPharma Website: https://abvcpharma.com/?page_id=17615
Youtube: https://youtu.be/QZ754OpWC7E?si=dews4u1fMpAENWDG
According to Global Market Insights, Antidepressant Drugs Market size exceeded
About
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the
Contact:
Email: leedschow@ambrivis.com
[1] https://www.gminsights.com/industry-analysis/antidepressant-drugs-market
Source:
2023 GlobeNewswire, Inc., source